Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
28 February 2023 | Story Lunga Luthuli and Nonsindiso Qwabe | Photo Sonia Small
Prof Francis Petersen
University of the Free State Rector and Vice-Chancellor, Prof Francis Petersen, addressing first-entry first-year students at this year’s official welcoming and Dream Walk event hosted on the Bloemfontein and Qwaqwa campuses.

‘Welcome to the Kovsie Land. This is the university of your future.’ These words reverberated across the University of the Free State’s (UFS) two campuses as Rector and Vice-Chancellor, Prof Francis Petersen, welcomed first-year students to the beginning of their journey to success.

During the annual official welcoming and the second Dream Walk, known as Kovsie Dream, the UFS welcomed first-year students to the university community on the Bloemfontein and Qwaqwa Campuses over two weekends, emphasizing clarity and the committed pursuit of their dreams and aspirations. 

University, a step towards harnessing personal development

“University is a valuable stage of growth in your life and an important platform for you to mature and gain personal success. It is a meaningful day marking a new chapter in your life,” said Prof Petersen.

The First-Year welcoming event is an important day on the university’s calendar, and the Division of Student Affairs has pulled out all the stops to ensure that, as one of the most memorable and significant days of the student’s academic journey, it was marked with fanfare and the instilling of the Kovsie spirit and values. 

Prof Petersen committed the university to walking the journey with students to see them leave the institution as proud and thriving graduates and UFS alumni.

“Today you stand on the shoulders of many alumni who continue to excel in various fields, not only in South Africa, but on the continent and globally, such as 2016 Olympics gold medallist, Wayde van Niekerk, 2020 Paralympics silver medal winner, Louzanne Coetzee, Free State Cheetahs rugby star, Oupa Mohoje, and former Miss World, Rolene Strauss. The challenge I would like you to sign up for, is to promise yourself, your family, and the UFS that you will develop yourself and try to make society a better place,” added Prof Petersen.

He said: “As you begin your journey as Kovsies, I believe you will forge your path of excellence and expand your potential within the faculties that will be your primary academic home. At the University of the Free State, we inspire excellence and transform lives.”

Qwaqwa Campus dreamwalk

The University of the Free State management leading first-year students on the Qwaqwa Campus during the
Dream Walk, which also provided an opportunity to complete their dream cards, setting their goals and
future aspirations. (Photo: Sonia Small) 


Get set, dream and achieve your goals

From the Callie Human and Mandela Halls respectively, the students participated in a Dream Walk, grouped according to their colleges, having completed dream cards that set goals for their future. In a move to shape the future of student life on the Qwaqwa Campus, on- and off-campus students were incorporated into colleges. This is another fulfilment of the university’s mission to see all students participating fully in student activities and having a holistic campus life experience, regardless of where they stay.


In closing, Prof Petersen said: “At the University of the Free State, we are an institution focused on consistently renewing and reimaging ourselves to effectively impact the communities around us. We equip you for global platforms. We believe that the graduates can operate and exhibit themselves on platforms around the globe.”

The welcoming festivities were closed with serenades by Durban-born Afro-pop songstress and songwriter Azana, former UFS LLB student and UFS alumni, and Van Pletzen band. 

Watch the highlights from this year's welcoming:


News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept